~~<i id='34CCE2C7AC'><strike id='34CCE2C7AC'><tt id='34CCE2C7AC'><pre id='34CCE2C7AC'></pre></tt></strike></i>~~

Home» leisure time» comprehensive

comprehensive

author：explore 2025-09-06 05:46:08 Page View：8465

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Maisha Meds is a PBM, but don't call it that
Next article： Heart attack and stroke risk calculators need revising

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Dana Farber says 6 studies to be retracted and 31 corrected

CraigF.Walker/TheBostonGlobeAreviewofallegeddatamanipulationinstudiesinvolvingfourtopscientistsatDan

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

AlexHogan/STATTocontainthespreadofCovid-19,Alaskaisplanningtotripleitsnumberofcontacttracers.Utahhas